advertisement
Abstract #48582 Published in IGR 14-1
Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma
Tsimpida M; Hungerford J; Arora A; Cohen VEye 2011; 25: 1607-1611
PURPOSE: To report the results of ruthenium-106 plaque radiotherapy for iris malignant melanoma. METHODS: A retrospective study of 15 patients with pure iris melanoma treated with ruthenium-106 plaque radiotherapy from June 1998 to June 2006. The main outcome measures were tumour control and ocular complications. RESULTS: Of the 15 patients, 8 had biopsy-proven melanoma (6 incisional and 2 excisional biopsies). In the remaining seven patients enlargement of the lesion was documented. The median follow-up was 96 months (ranging from 14 months to 12 years). Common radiation-related complications included cataract in 9 (60%) patients, dry eyes in 3 (20%) patients and elevated intraocular pressure in 4 (27%) patients. Vision was preserved in 80% of patients. Local tumour control was obtained in all patients. CONCLUSIONS: Ruthenium-106 plaque radiotherapy is an effective treatment for primary malignant iris melanoma, resulting in excellent local control with preservation of vision. Main complications included cataract, dry eyes, and glaucoma.
Department of Ophthalmology, St Bartholomew's Hospital and Moorfields Eye Hospital, London, UK. maria.tsimpida@bartsandthelondon.nhs.uk
Full articleClassification:
9.4.8 Glaucomas associated with intraocular tumors (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)
2.8 Iris (Part of: 2 Anatomical structures in glaucoma)
